Thursday, May 19, 2022 2:56:07 PM
BB,
I believe there is another way that DI may know our investment is derisked that can't be discussed with investors, it's what he may know about the company's relationships with the 4 regulators. Frankly, companies just never discuss their discussions with the FDA or any other regulators, but I believe that there is more of it than anyone realizes. I believe that companies can sense how open the regulators are to their ideas, it's not a lock, but if they have a warm fuzzy feeling, it's likely to result in approval. I think DI would have a feel for this, even if he's not aware of all the specifics, but even if he were, it's not something he could talk about.
I'm not suggesting that other possibilities aren't possible, I prefer a partnership to buyout, but either may already be in the cards when certain conditions have been met. The question is, what are those conditions, and are they keyed to events like approval, or simply reaching a certain trigger price regardless of where we are in the process. Only those privy to the negotiations would know.
Gary
I believe there is another way that DI may know our investment is derisked that can't be discussed with investors, it's what he may know about the company's relationships with the 4 regulators. Frankly, companies just never discuss their discussions with the FDA or any other regulators, but I believe that there is more of it than anyone realizes. I believe that companies can sense how open the regulators are to their ideas, it's not a lock, but if they have a warm fuzzy feeling, it's likely to result in approval. I think DI would have a feel for this, even if he's not aware of all the specifics, but even if he were, it's not something he could talk about.
I'm not suggesting that other possibilities aren't possible, I prefer a partnership to buyout, but either may already be in the cards when certain conditions have been met. The question is, what are those conditions, and are they keyed to events like approval, or simply reaching a certain trigger price regardless of where we are in the process. Only those privy to the negotiations would know.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
